212 related articles for article (PubMed ID: 38177929)
1. Illuminating phenotypic drug responses of sarcoma cells to kinase inhibitors by phosphoproteomics.
Lee CY; The M; Meng C; Bayer FP; Putzker K; Müller J; Streubel J; Woortman J; Sakhteman A; Resch M; Schneider A; Wilhelm S; Kuster B
Mol Syst Biol; 2024 Jan; 20(1):28-55. PubMed ID: 38177929
[TBL] [Abstract][Full Text] [Related]
2. Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors.
Balabanov S; Wilhelm T; Venz S; Keller G; Scharf C; Pospisil H; Braig M; Barett C; Bokemeyer C; Walther R; Brümmendorf TH; Schuppert A
PLoS One; 2013; 8(1):e53668. PubMed ID: 23326482
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.
Radic-Sarikas B; Tsafou KP; Emdal KB; Papamarkou T; Huber KV; Mutz C; Toretsky JA; Bennett KL; Olsen JV; Brunak S; Kovar H; Superti-Furga G
Mol Cancer Ther; 2017 Jan; 16(1):88-101. PubMed ID: 28062706
[TBL] [Abstract][Full Text] [Related]
4. Investigation of cancer drug resistance mechanisms by phosphoproteomics.
Boulos JC; Yousof Idres MR; Efferth T
Pharmacol Res; 2020 Oct; 160():105091. PubMed ID: 32712320
[TBL] [Abstract][Full Text] [Related]
5. Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA).
Hallal M; Braga-Lagache S; Jankovic J; Simillion C; Bruggmann R; Uldry AC; Allam R; Heller M; Bonadies N
BMC Cancer; 2021 Jul; 21(1):789. PubMed ID: 34238254
[TBL] [Abstract][Full Text] [Related]
6. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA
Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294
[TBL] [Abstract][Full Text] [Related]
7. Polypharmacology-based ceritinib repurposing using integrated functional proteomics.
Kuenzi BM; Remsing Rix LL; Stewart PA; Fang B; Kinose F; Bryant AT; Boyle TA; Koomen JM; Haura EB; Rix U
Nat Chem Biol; 2017 Dec; 13(12):1222-1231. PubMed ID: 28991240
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoproteomic characterisation of human colon and rectal cancer.
Frejno M; Zenezini Chiozzi R; Wilhelm M; Koch H; Zheng R; Klaeger S; Ruprecht B; Meng C; Kramer K; Jarzab A; Heinzlmeir S; Johnstone E; Domingo E; Kerr D; Jesinghaus M; Slotta-Huspenina J; Weichert W; Knapp S; Feller SM; Kuster B
Mol Syst Biol; 2017 Nov; 13(11):951. PubMed ID: 29101300
[TBL] [Abstract][Full Text] [Related]
9. Establishment and proteomic characterization of patient-derived clear cell sarcoma xenografts and cell lines.
Sakumoto M; Oyama R; Takahashi M; Takai Y; Kito F; Shiozawa K; Qiao Z; Endo M; Yoshida A; Kawai A; Kondo T
In Vitro Cell Dev Biol Anim; 2018 Feb; 54(2):163-176. PubMed ID: 29197033
[TBL] [Abstract][Full Text] [Related]
10. Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors.
Casado P; Alcolea MP; Iorio F; Rodríguez-Prados JC; Vanhaesebroeck B; Saez-Rodriguez J; Joel S; Cutillas PR
Genome Biol; 2013 Apr; 14(4):R37. PubMed ID: 23628362
[TBL] [Abstract][Full Text] [Related]
11. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM
Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 clinical trials for sarcomas: the cutting edge.
Subbiah V; Kurzrock R
Curr Opin Oncol; 2011 Jul; 23(4):352-60. PubMed ID: 21519259
[TBL] [Abstract][Full Text] [Related]
13. Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics.
Gridling M; Ficarro SB; Breitwieser FP; Song L; Parapatics K; Colinge J; Haura EB; Marto JA; Superti-Furga G; Bennett KL; Rix U
Mol Cancer Ther; 2014 Nov; 13(11):2751-62. PubMed ID: 25189542
[TBL] [Abstract][Full Text] [Related]
14. Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors.
Reinecke M; Brear P; Vornholz L; Berger BT; Seefried F; Wilhelm S; Samaras P; Gyenis L; Litchfield DW; Médard G; Müller S; Ruland J; Hyvönen M; Wilhelm M; Kuster B
Nat Chem Biol; 2024 May; 20(5):577-585. PubMed ID: 37904048
[TBL] [Abstract][Full Text] [Related]
15. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.
Bai Y; Li J; Fang B; Edwards A; Zhang G; Bui M; Eschrich S; Altiok S; Koomen J; Haura EB
Cancer Res; 2012 May; 72(10):2501-11. PubMed ID: 22461510
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.
Shor AC; Agresta SV; D'Amato GZ; Sondak VK
Cancer Control; 2008 Jan; 15(1):47-54. PubMed ID: 18094660
[TBL] [Abstract][Full Text] [Related]
17. Proteomic research in sarcomas - current status and future opportunities.
Burns J; Wilding CP; L Jones R; H Huang P
Semin Cancer Biol; 2020 Apr; 61():56-70. PubMed ID: 31722230
[TBL] [Abstract][Full Text] [Related]
18. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
19. Histology-specific therapy for advanced soft tissue sarcoma and benign connective tissue tumors.
Silk AW; Schuetze SM
Curr Treat Options Oncol; 2012 Sep; 13(3):285-98. PubMed ID: 22610342
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine and phosphoproteomics for the identification of novel targeted therapeutic avenues in sarcomas.
Fordham AM; Ekert PG; Fleuren EDG
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188613. PubMed ID: 34390800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
